Knight Therapeutics Inc. (TSE:GUD – Get Free Report) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as C$6.25 and last traded at C$6.18, with a volume of 43828 shares traded. The stock had previously closed at C$6.17.
Wall Street Analyst Weigh In
Separately, Research Capitl upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 11th. Two analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Knight Therapeutics currently has a consensus rating of “Strong Buy” and a consensus price target of C$7.08.
Get Our Latest Analysis on GUD
Knight Therapeutics Stock Up 0.6 %
Insider Activity at Knight Therapeutics
In other news, insider Sime Armoyan purchased 17,600 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average price of C$5.48 per share, for a total transaction of C$96,488.48. 45.62% of the stock is owned by company insiders.
About Knight Therapeutics
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
- Five stocks we like better than Knight Therapeutics
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Must-Own Stocks to Build Wealth This Decade
- Roth IRA Calculator: Calculate Your Potential Returns
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.